Full Text View
Tabular View
No Study Results Posted
Related Studies
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
This study has been completed.
Study NCT01445405   Information provided by National Institutes of Health Clinical Center (CC)

First Received on September 30, 2011.   Last Updated on May 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Squamous
Head and Neck Cancer
Oral Cancer
Laryngeal Cancer
Pharyngeal Cancer
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Laryngeal Neoplasms
Lip Neoplasms
Mouth Neoplasms
Pharyngeal Neoplasms
More general conditions related to this trial
Laryngeal Diseases
Lip Diseases
Mouth Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Otorhinolaryngologic Diseases
Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Stomatognathic Diseases
Interventions listed in this trial
Bortezomib (Velcade, PS-341)
Cetuximab
Cisplatin
Radiation Therapy
Additional drug interventions recognized in this trial
Bortezomib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services